Rotavirus vaccination programmes

BMJ (Online)

Volumn 345, Issue 7872, 2012, Pages

  Patel, Manish M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; ROTAVIRUS VACCINE; VIRUS DNA;

BELGIUM; COST BENEFIT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INTUSSUSCEPTION; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ROTAVIRUS; ROTAVIRUS INFECTION; SOCIOECONOMICS; VACCINATION; VIRUS STRAIN;

FEMALE; GASTROENTERITIS; HUMANS; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84865718287     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5286     Document Type: Editorial

References (12)

1. Braeckman T, Van Herck K, Meyer N, Pirçon J-Y, Soriano-Gabarró M, Heylen E, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012;345:e4752.
2. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;2:1281-3.
3. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:136-41.
4. WHO. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009;84:533-40.
5. Patel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis 2012;12:561-70.
6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
7. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
8. Grimwood K, Kirkwood CD. Human rotavirus vaccines: too early for the strain to tell. Lancet 2008;371:1144-5.
9. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista Marquez A, Flannery B, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364:2283-92.
10. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29:3061-6.
11. Kuehn BM. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010;304:30-1.
12. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009;200(suppl 1):S39-48.